Stem cell transplant using your own cells for AL amyloidosis
Part of Blood & lymphatic, Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–75 years old
- You have newly diagnosed AL amyloidosis
- Your blood or urine tests show abnormal M protein or abnormal free light chains
- A specialist says you are a good candidate for an autologous stem cell transplant
- Your daily function is fairly good (ECOG 0–2)
- You can (or your legal representative can) sign consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This early-stage trial tests a new drug called anselamimab for AL amyloidoma—a rare condition where abnormal protein deposits form tumors in one part of your body. The study aims to see if this drug can help shrink or control these deposits in patients who have a visible, removable tumor.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a new cell therapy called FKC288 for people with AL amyloidosis that hasn't been helped by standard treatments. The goal is to see if it can safely control the disease and improve organ function.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.